Goldberg David, Reese Peter P
Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania.
Semin Dial. 2019 Mar;32(2):179-186. doi: 10.1111/sdi.12767. Epub 2018 Nov 26.
Utilization of kidneys from hepatitis C virus (HCV)-infected deceased donors has the potential to increase the number of kidney transplants by 500-1000 (or more) each year. This increase in the number of kidney transplants offers major opportunities to extend survival and improve quality of life for patients infected with HCV, as well as uninfected recipients. However, due to a lack of prospective safety and efficacy data on a sufficient number of HCV-negative recipients who received a kidney from a HCV-infected donor, as well as key logistical barriers, the practice of transplanting HCV-infected organs into uninfected recipients is not yet ready to be considered as standard of care. Ongoing research coupled with a collaboration between insurers and transplant centers might bring positive-into-negative transplant into the realm of standard of care in well-informed transplant candidates, regardless of HCV status.
利用丙型肝炎病毒（HCV）感染的已故供体的肾脏，每年有可能使肾移植数量增加500 - 1000例（或更多）。肾移植数量的增加为延长HCV感染患者以及未感染受者的生存期和改善生活质量提供了重大机遇。然而，由于缺乏关于足够数量接受HCV感染供体肾脏的HCV阴性受者的前瞻性安全性和有效性数据，以及关键的后勤障碍，将HCV感染器官移植给未感染受者的做法尚未准备好被视为标准治疗方法。正在进行的研究以及保险公司与移植中心之间的合作，可能会使在充分知情的移植候选者中，无论其HCV状态如何，将阳性供体移植给阴性受者进入标准治疗的范畴。
